TCTMD’s Top 10 Most Popular Stories for March 2023
All but one of our most-read stories this month stemmed from the ACC/WCC 2023 meeting in New Orleans, LA.
Our most-read story in March, delving into the cardiovascular benefits of a Mediterranean diet in women, was the only one that had nothing to do with conference coverage. Every other story on the list this month stemmed from late-breaking clinical trials and other high-impact studies presented at the American College of Cardiology/World Congress of Cardiology (ACC/WCC) 2023 meeting.
The results may not be surprising, but even so these kinds of analyses are important ways to validate that gender doesn’t have a major impact when it comes to diet, one expert said.
After 5 years, TEER-treated patients still have the edge over controls, but with so many having passed away or elected to get the procedure at 2 years, a new randomized controlled trial would help answer some pressing questions.
The reduction in “hard” events in RENOVATE-COMPLEX-PCI caught some off guard, but these findings will only bolster calls for routine IVUS or OCT during PCI.
In a small, randomized study, statins prevented progressive LVEF dysfunction over 12 months across a range of subgroups, raising hopes that the agents might provide some protection for cancer patients.
The US Food and Drug Administration required a CV outcomes trial to show the already approved drug reduced the risk of MACE. The results are in, suggesting another nonstatin agent might be helpful in this setting.
The trial establishes that TEER for tricuspid regurgitation is safe and effective, but to the surprise of some observers, quality-of-life improvements were what drove the primary endpoint, rather than the “harder” gains seen in the mitral space.
There was a higher rate of MI among patients undergoing staged revascularization procedures, but that might reflect operators misjudging the culprit lesion.
An adjuvant anti-inflammatory might offer more protection than additional lipid-lowering, a meta-analysis hints, a reminder that remains room for other types of agents to help bring down residual risk.
Though not randomized, this new trial suggested that remote monitoring of thoracic fluid buildup might allow for strategies such as medication adjustments that would prevent patients from needing return to hospital.
Intensified LDL-lowering upped fibrous cap thickness on OCT and cut lipid burden on NIRS. The bigger goal will be linking plaque characteristics with easier-to-measure biomarkers that could be used to predict who benefits most from aggressive lipid-lowering.